Synairgen plc: Synairgen announces positive data from the US

Fewer participants treated with SNG001 compared to placebo progressed to hospitalisation (1/110 vs 7/110, P=0.07) SNG001 was well-tolerated with a favourable safety profile consistent with

Related Keywords

Namrata Taak , Geoff Nash , Mary Conway , Richard Marsden , Donna Davies , Duncan Monteith , Brooke Clarke , William Fischer , James Black , Mary Jane Elliott , Ratko Djukanovic , Freddie Barnfield , Lucy Featherstone , Numis Securities Limited Joint Broker , Head Of Communications , National Institutes Of Health , Clinical Trials Group , Drug Administration , University Of North Carolina , Consilium Strategic Communications Financial Media , Mkc Strategies Llc Us Media Relations , University Of Southampton Professors Sir Stephen Holgate , Us National Institutes Of Health , Trials Group , Adverse Events , Independent Data Safety Monitoring Board , North Carolina , United Kingdom Based , Fast Track , Southampton Professors Sir Stephen Holgate , Platform Treatment Trial , National Institutes , Joint Broker , Charlie Beeson , Corporate Finance , Sunil De Silva , Securities Limited , Strategic Communications , Financial Media , Investor Relations , Jane Elliott , Synairgen , Nnounces , Positive , Data , Rom , Eactiv , Hase , Trial , Sng001 , Rome , Ased , Participants , Covid ,